CA-VERACODE
1.5.2024 14:51:32 CEST | Business Wire | Press release
Veracode, a global leader in application risk management, today announced platform innovations that set a new standard for developer-powered application security. New repo risk visibility and analysis from Longbow Security, powered by Veracode, speeds up remediation of application risk from code repositories to runtime images. The solution launches alongside Veracode Fix in the Integrated Development Environment (IDE) and Batch Fix to bridge the gap between development and security teams. These latest innovations help developers focus on the most critical tasks that drive value and differentiation.
“Developers today face significant competing pressures to innovate faster and perform more security checks on their code than ever before,” said Tim Jarrett, Group Head of Product Management at Veracode. “We are committed to a frictionless experience for developers and security operators and our latest product enhancements make the job of securing code simple and seamless.”
Bringing Developer & Security Teams Together: Repo Risk Visibility & Analysis
In April, Veracode acquired Longbow Security to help organizations effectively manage and reduce application risk across the growing attack surface. The integration of Longbow’s newest capability, repo risk visibility and analysis, bridges the gap between development and security teams with enhanced visibility from code repositories to cloud assets and runtime images. It also illuminates infrastructure-as-code and misconfiguration risk for cloud assets originating from repositories.
“Customers challenged us to apply our unique cloud risk and prioritization expertise from Longbow to problems they face managing upstream risk in their code repositories,” said Derek Maki, Vice President of Product Management at Veracode. “We responded with a solution that gives visibility into the relationship between source code weaknesses and runtime security posture. Simultaneously, development teams get a consolidated view of risk and huge time savings when it comes to prioritizing remediation, reducing code changes, and fixing issues fast.”
This new feature complements Veracode’s latest innovation for GitHub repo scanning, which enables developers to streamline activities like staging servers and environments so they don’t need to scan every time. This makes it easier for development and security teams to collaborate on secure coding and scanning as Veracode results are delivered to GitHub where developers can act immediately.
Security Debt Reduction: Veracode Fix in the IDE & Batch Fix
Research shows 92 percent of U.S.-based developers are already using artificial intelligence (AI) coding tools both in and outside of work, with generative AI helping software engineers write code 35-45 percent faster. At the same time, other research suggests code developed by AI contains the same percentage of security flaws as that generated by humans.
Veracode was the first company to deliver a solution that provides developers with AI-generated secure code fixes. Since launching Veracode Fix at RSA Conference last year, hundreds of customers have used the solution to reduce their backlog of security debt and risk. Ninety-two percent of CWEs (Common Weakness Enumeration) with a severity rating from medium to very high can be addressed through AI-generated code edits from Veracode Fix.
With the introduction of Veracode Fix in the IDE, developers can now fix flaws faster with AI-suggested remediation right in the IDE, without switching applications or researching alternative code options. Fixes can be made before code is pushed through the software development lifecycle, dramatically cutting the time and cost spent fixing flaws compared to retroactive remediation.
Batch Fix enables bulk AI-assisted remediation of flaws in source code across multiple flaws and files in one operation. This makes remediation of flaws an order of magnitude faster, aiding the reduction of security debt at scale. For example, developers can use it to fix a CWE that requires an easy-to-test resolution and run it across multiple source files at once.
Jarrett closed, “With these latest innovations, Veracode meets developers where they are—in the tools they use daily—to help them secure the code they create today, without compromising productivity. This vastly improves efficiency and velocity, fostering a culture of collaboration and trust between development and security teams.”
Repo Risk Visibility & Analysis, Veracode Fix in the IDE, and Batch Fix are available immediately. For more information, please visit the Veracode blog.
Visitors to RSA Conference can learn more about Veracode’s platform and these new features by visiting Veracode’s booth #2045 in the main hall.
About Veracode
Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501107223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
